Standard BioTools Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Standard BioTools Inc. (LAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.90 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-16
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.90, a 54.08% decline from fiscal 2024.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.96, a 31.54% increase from fiscal 2023.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.49, a 32.58% decline from fiscal 2022.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.21, a 40.75% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2025-12-31 | $0.90 10-K · filed 2026-03-16 | ||
| 2024-12-31 | $1.96 10-K · filed 2026-03-16 | ||
| 2023-12-31 | $1.49 10-K · filed 2026-03-16 | ||
| 2022-12-31 | $2.21 10-K · filed 2025-03-11 | ||
| 2021-12-31 | $3.73 10-K · filed 2023-03-14 | ||
| 2020-12-31 | $2.60 10-K · filed 2022-03-08 | ||
| 2019-12-31 | $7.17 10-K · filed 2022-03-08 | ||
| 2019-09-30 | $7.17 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $7.36 10-Q · filed 2019-08-07 | ||
| 2018-12-31 | $3.45 10-K · filed 2021-02-25 | ||
| 2017-12-31 | $2.97 10-K · filed 2020-02-27 | ||
| 2016-12-31 | $3.19 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |